COGNITO THERAPEUTICS

Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease

Retrieved on: 
Tuesday, March 8, 2022
Software, Biotechnology, Pharmaceutical, Health, Mental Health, Data Management, Technology, Clinical Trials, Risk, Warburg Pincus, Harvard Medical School, Patient, Research, Cognito, Prevalence, MCI, New Enterprise Associates, Twitter, UCB, Neurodegeneration, Alzheimer's disease, Safety, MIT, Medicare, Foresite Capital, Dementia, FDA, Therapy, Optogenetics, Multimedia, RWE, CEO, Epidemiology, Technology, Partnership, Johnson & Johnson, NEA, Medical device, Pharmaceutical industry, Aetion, Shiga Lakestars, Greenspring Associates, Cognito Therapeutics, Aetion, Cognito Therapeutics, Aetion, COGNITO THERAPEUTICS, AETION

MCI represents the top contributor to Alzheimer's prevalence, which currently costs the US healthcare system $305 billion per year.

Key Points: 
  • MCI represents the top contributor to Alzheimer's prevalence, which currently costs the US healthcare system $305 billion per year.
  • Aetion is a recognized global leader in transforming real-world data into RWE and in predictive analytics and health economic modeling.
  • We are proud to partner with Cognito Therapeutics, who are developing novel therapies for neurodegenerative diseases, said Carolyn Magill, CEO, Aetion.
  • Cognito Therapeutics is a pioneer in disease-modifying therapeutic interventions for neurodegenerative diseases and human cognitive performance.

Cognito Therapeutics and Providence Health Plan Launch Phase 3 Study to Evaluate Disease-Modifying Therapeutic in Mild Cognitive Impairment

Retrieved on: 
Thursday, January 27, 2022
Nursing, Women, Data Management, Other Science, Physical Therapy, FDA, Technology, Research, Managed Care, Consumer, Pharmaceutical, Mental Health, Hospitals, Genetics, Fitness & Nutrition, Biotechnology, Software, Health, Science, Hardware, Cognito, CEO, MIT, Neurodegeneration, PHP, Organization, Ageing, Research, Medicare, Health, Multimedia, Dementia, Therapy, Center, Twitter, Providence Health & Services, Patient, AD, FDA, Optogenetics, CMO, MCI, Medicaid, Safety, Medical device, Pharmaceutical industry, Cognito Therapeutics, Providence Health Plan, COGNITO THERAPEUTICS, PROVIDENCE HEALTH PLAN

Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognitos breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI).

Key Points: 
  • Cognito Therapeutics and Providence Health Plan today announced a collaboration to conduct a Phase 3 study of Cognitos breakthrough, non-invasive disease-modifying therapy for patients with Mild Cognitive Impairment (MCI).
  • We look forward to collaborating with Providence Health Plan on our Phase 3 programs evaluating our disease-modifying intervention across the full spectrum of patients from MCI to mild to moderate Alzheimers, said Brent Vaughan, CEO, Cognito Therapeutics.
  • This newly launched study with Providence Health Plan is part of a larger multi-study Phase 3 program evaluating Cognitos disease-modifying optogenetics-based therapeutic in patients with MCI and mild-to-moderate AD.
  • We offer a range of benefits including comprehensive health care, 24/7 access to telehealth visits, behavioral health resources and personalized health coaching.